Edition:
United Kingdom

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

5.10USD
22 Jun 2018
Change (% chg)

$-0.06 (-1.16%)
Prev Close
$5.16
Open
$5.18
Day's High
$5.24
Day's Low
$4.88
Volume
365,723
Avg. Vol
242,594
52-wk High
$19.30
52-wk Low
$3.76

Chart for

About

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $387.58
Shares Outstanding(Mil.): 36.22
Dividend: --
Yield (%): --

Financials

  NLNK.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -2.29 -- --
ROI: -50.00 2.00 14.38
ROE: -52.94 3.49 16.08

BRIEF-Newlink Genetics Corp Reports Qtrly Loss Per Share Of $0.49

* NEWLINK GENETICS CORP QTRLY BASIC AND DILUTED LOSS PER SHARE $0.49

03 May 2018

BRIEF-Newlink Genetics Appoints Matthew Sherman To Board

* NEWLINK GENETICS - IN CONNECTION WITH APPOINTMENT OF MATTHEW SHERMAN TO CO'S BOARD, BOARD WILL BE COMPRISED OF EIGHT DIRECTORS Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Newlink Genetics Reviews Clinical Programs

* IN LIGHT OF INCYTE'S ANNOUNCEMENT REGARDING ECHO-301 TRIAL, CO UNDERTAKING REVIEW OF CLINICAL PROGRAMS Source text for Eikon: Further company coverage:

06 Apr 2018

BRIEF-NewLink Genetics, Cantor Fitzgerald Enter Controlled Equity Offering Sales Agreement

* NEWLINK GENETICS SAYS ON MARCH 12, CO ENTERED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING

13 Mar 2018

BRIEF-NewLink Genetics Qtrly Loss Per Share $0.37

* NEWLINK GENETICS REPORTS FOURTH QUARTER, YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES UPDATE FOR INDOXIMOD PROGRAMS

01 Mar 2018

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

08 Jan 2018

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,758 +2.00
Pfizer Inc. (PFE.N) $36.51 +0.21
Novartis AG (NOVN.S) CHF75.60 +0.10
Merck & Co., Inc. (MRK.N) $61.47 +0.29
Roche Holding Ltd. (ROG.S) CHF216.45 --
Roche Holding Ltd. (RO.S) CHF223.60 +4.00
Abbott Laboratories (ABT.N) $61.94 +0.19
Sanofi SA (SASY.PA) €69.01 +1.30
AstraZeneca plc (AZN.L) 5,229.00 -26.00
GlaxoSmithKline plc (GSK.L) 1,546.00 +7.60

Earnings vs. Estimates